Core Viewpoint - The company, Yuan Da Pharmaceutical, has made significant progress in the development of global innovative nuclear medicines, with the announcement of its Chengdu Wenjiang nuclear medicine global R&D and production base receiving a Class A "Radiation Safety License" from the National Ecological Environment Department, set to commence operations in June 2025 [1][2] Group 1 - The Chengdu Wenjiang base is positioned as a global highland for the industrialization of innovative nuclear medicines, being the world's first "zero radiation" intelligent nuclear medicine factory with a full-process radiation monitoring system meeting nuclear power safety standards [1] - The base covers an area of 50 acres, with the first phase utilizing 25 acres, and a total planned investment exceeding 3 billion yuan, focusing on isotope process development, nuclear medicine coupling technology, and automated labeling technology [2] - The construction includes 14 high-standard GMP production lines capable of producing various isotopes such as 18F, 64Cu, and 89Zr, while also reserving production lines for alpha-emitting radiopharmaceuticals to meet diverse therapeutic and diagnostic nuclear medicine needs [2]
港股异动 | 远大医药(00512)高开逾3% 全球首个“零辐射”智能核药工厂将于6月正式投入运营